Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Date:

November 14, 2024

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.

Source link

Which 'Young Sheldon' Easter Egg Did Fans Miss on 'Georgie and Mandy'?

Tropical Storm Sara forms in Caribbean, could threaten Florida next week

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Recent posts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

5 things investors learned from JPMorgan Chase’s earnings

Bond market participants brace for bigger deficits under either Trump or Biden

Businesses and families want these tax breaks. Congress might not deliver until at least next year.

Hurricane Beryl puts focus on oil with climate change likely to intensify storms

Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims

Eli Lilly’s Zepbound pricing shuffle leaves some patients fearing higher costs

Gold prices look to settle at 1-month high as silver jumps nearly 4%

Treasury’s stable coupon, auction sizes at risk from U.S. election results

Israeli strikes on Iran’s ‘oil island’ could send crude prices soaring

Why hasn’t Kamala Harris already executed her economic plans? U.S. first had to recover from COVID, she says.

This week’s U.S. inflation report could have serious implications for stocks

Nike stock falls, as executives say Q4 results ‘highlighted challenges’ with demand

Stocks usually see double-digit gains under U.S. presidents — with two exceptions since 1933

Abercrombie & Fitch to see earnings ‘upside,’ but there’s potential margin pressure ahead: analyst

Related articles

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Company

Follow us